| Hyperparathyroidism, Secondary
Zemplar vs Rayaldee
Side-by-side clinical, coverage, and cost comparison for hyperparathyroidism, secondary.Deep comparison between: Zemplar vs Rayaldee with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayaldee has a higher rate of injection site reactions vs Zemplar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayaldee but not Zemplar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zemplar
Rayaldee
At A Glance
Oral
Daily or three times weekly
Vitamin D analog
Oral
Daily
Vitamin D3 analog
Indications
- Hyperparathyroidism, Secondary
- Hyperparathyroidism, Secondary
Dosing
Hyperparathyroidism, Secondary (CKD Stages 3-4, Adults) Initial: 1 mcg orally daily or 2 mcg three times weekly if iPTH <=500 pg/mL; 2 mcg orally daily or 4 mcg three times weekly if iPTH >500 pg/mL. Titrate: Increase by 1 mcg daily or 2 mcg three times weekly if iPTH unchanged or changed <30%; maintain dose if iPTH decreased 30-60%; decrease by 1 mcg daily or 2 mcg three times weekly if iPTH decreased >60% or iPTH <60 pg/mL.
Hyperparathyroidism, Secondary (CKD Stage 5, Adults) Initial: Dose (mcg) = baseline iPTH (pg/mL) divided by 80, administered orally three times weekly (no more frequently than every other day). Ensure baseline serum calcium <=9.5 mg/dL. Titrate: Dose (mcg) = most recent iPTH (pg/mL) divided by 80; decrease by 2-4 mcg if serum calcium is elevated.
Hyperparathyroidism, Secondary (CKD Stages 3-4, Pediatric 10-16 years) Initial: 1 mcg orally three times weekly, no more frequently than every other day. Titrate: Increase each dose by 1 mcg three times weekly every 4 weeks or decrease by 1 mcg three times weekly at any time based on iPTH, serum calcium and phosphorus levels.
Hyperparathyroidism, Secondary (CKD Stage 5, Pediatric 10-16 years) Initial: Dose (mcg) = baseline iPTH (pg/mL) divided by 120 (round down), administered orally three times weekly, no more frequently than every other day. Titrate: Increase each dose by 1 mcg three times weekly every 4 weeks or decrease by 2 mcg three times weekly at any time based on iPTH, serum calcium and phosphorus levels.
Hyperparathyroidism, Secondary Initial dose 30 mcg orally once daily at bedtime; increase to 60 mcg once daily after approximately 3 months if intact PTH remains above the desired therapeutic range.
Contraindications
- Hypercalcemia
- Vitamin D toxicity
—
Adverse Reactions
Most common (>=5%) in CKD Stages 3-4 Vertigo (5%), diarrhea (7%), nausea (6%), vomiting (5%), edema (6%), hypersensitivity (6%), viral infection (7%), arthritis (5%), dizziness (5%), headache (5%), hypertension (7%), hypotension (5%)
Most common (>=5%) in CKD Stage 5 Diarrhea (11%), nasopharyngitis (8%), dizziness (7%), vomiting (7%), peritonitis (5%), fluid overload (5%), insomnia (5%), constipation (5%)
Postmarketing Angioedema (including laryngeal edema), blood creatinine increased
Most common (>=1.4%) Anemia, Nasopharyngitis, Blood creatinine increased, Dyspnea, Cough, Cardiac failure congestive, Constipation, Bronchitis, Hyperkalemia, Osteoarthritis, Hyperuricemia, Contusion, Pneumonia, Chronic obstructive pulmonary disease
Serious Hypercalcemia, Adynamic Bone Disease
Pharmacology
Paricalcitol is a synthetic vitamin D2 analog that binds to the vitamin D receptor (VDR), selectively activating vitamin D responsive pathways, inhibiting PTH synthesis and secretion, thereby reducing parathyroid hormone levels in secondary hyperparathyroidism.
Calcifediol is a prohormone of vitamin D3 that is converted by CYP27B1 in the kidney to calcitriol, which binds to the vitamin D receptor and activates pathways that increase intestinal absorption of calcium and phosphorus and reduce parathyroid hormone synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zemplar
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Rayaldee
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Zemplar
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Rayaldee
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Zemplar
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Rayaldee
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Zemplar.
Cost estimate not availableHealthWell: Secondary Hyperparathyroidism
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZemplarView full Zemplar profile
RayaldeeView full Rayaldee profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.